RSV continues to be a focus area within respiratory health with the release of new vaccines and therapeutics. As leading experts in infectious disease and respiratory drug development the teams at Lovelace and Gilead recently published some work on GS-7682 to target RSV. We are excited about this work as it directly impacts respiratory health. If you have interests in similar programs please reach out to Lovelace Biomedical.